[go: up one dir, main page]

DE69125925D1 - Rekombinante herpes simplex virus impfstoffe und methoden - Google Patents

Rekombinante herpes simplex virus impfstoffe und methoden

Info

Publication number
DE69125925D1
DE69125925D1 DE69125925T DE69125925T DE69125925D1 DE 69125925 D1 DE69125925 D1 DE 69125925D1 DE 69125925 T DE69125925 T DE 69125925T DE 69125925 T DE69125925 T DE 69125925T DE 69125925 D1 DE69125925 D1 DE 69125925D1
Authority
DE
Germany
Prior art keywords
herpes simplex
simplex virus
methods
virus vaccine
recombinant herpes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69125925T
Other languages
English (en)
Other versions
DE69125925T2 (de
Inventor
Bernard Roizman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24318537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69125925(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arch Development Corp filed Critical Arch Development Corp
Application granted granted Critical
Publication of DE69125925D1 publication Critical patent/DE69125925D1/de
Publication of DE69125925T2 publication Critical patent/DE69125925T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69125925T 1990-09-10 1991-09-10 Rekombinante herpes simplex virus impfstoffe und methoden Expired - Lifetime DE69125925T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/579,834 US5328688A (en) 1990-09-10 1990-09-10 Recombinant herpes simplex viruses vaccines and methods
PCT/US1991/006532 WO1992004050A1 (en) 1990-09-10 1991-09-10 Recombinant herpes simplex viruses vaccines and methods

Publications (2)

Publication Number Publication Date
DE69125925D1 true DE69125925D1 (de) 1997-06-05
DE69125925T2 DE69125925T2 (de) 1997-09-25

Family

ID=24318537

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69125925T Expired - Lifetime DE69125925T2 (de) 1990-09-10 1991-09-10 Rekombinante herpes simplex virus impfstoffe und methoden

Country Status (11)

Country Link
US (2) US5328688A (de)
EP (1) EP0500917B1 (de)
JP (1) JP3334876B2 (de)
AT (1) ATE152355T1 (de)
AU (1) AU658838B2 (de)
CA (1) CA2072627C (de)
DE (1) DE69125925T2 (de)
DK (1) DK0500917T3 (de)
ES (1) ES2102409T3 (de)
GR (1) GR3024144T3 (de)
WO (1) WO1992004050A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
DE69332525T2 (de) * 1992-03-31 2003-04-17 Arch Development Corp., Chicago Behandlung von Tumorerkrankungen mit modifiziertem HSV
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
DE69332678T2 (de) * 1992-12-23 2004-02-05 Arch Development Corp., Chicago Synthetische promotoren von herpes simplex virus
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
WO1997009999A1 (en) * 1995-09-11 1997-03-20 Aviron Methods and compositions for treatment of hsv-2 infections and conditions
WO1997026904A1 (en) * 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
CA2284611A1 (en) * 1997-03-27 1998-10-01 Richard B. Pyles Replication-competent herpes simplex viruses
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
JP2002516061A (ja) 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
US6051385A (en) * 1997-10-22 2000-04-18 The Regents Of The University Of Michigan Compositions and methods for identifying and testing therapeutics against HSV infection
US6399354B1 (en) * 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
WO2000040734A1 (en) * 1998-12-31 2000-07-13 Arch Development Corporation Recombinant herpes simplex virus useful for treating neoplastic disease
EP1150696B1 (de) * 1999-02-05 2006-05-10 Arch Development Corporation Genetische manipulierte herpesviren zur behandlung von tumoren
US6774119B1 (en) 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
CA2378519C (en) 1999-07-07 2011-01-25 Zymogenetics, Inc. Human cytokine receptor
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
DE60107203T3 (de) * 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
AU2001239884B2 (en) * 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
US6516246B2 (en) * 2000-09-11 2003-02-04 Mimicking Man Manually, Inc. Method and system for determining native neurological dominant hemisphere
US6846670B2 (en) 2000-11-28 2005-01-25 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
EA010594B1 (ru) 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
CA2476724A1 (en) * 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1552016A4 (de) * 2002-09-23 2008-05-14 Macrogenics Inc Verfahren zur impfstoffidentifizierung sowie nukleinsäure- und/oder polypeptidsequenzen der herpesvirus-familie umfassende zusammensetzungen zur impfung
WO2004029258A1 (en) * 2002-09-27 2004-04-08 Powderject Research Limited Nucleic acid constructs for gene expression
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
AU2003282691A1 (en) * 2002-10-07 2004-05-04 University Of Chicago Targeting of herpes simplex virus to specific receptors
US7592169B2 (en) * 2003-04-25 2009-09-22 Medimmune, Llc Methods and compositions for treatment and prevention of HSV-2 infections and conditions
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
AU2004272114B2 (en) * 2003-09-12 2010-11-04 Vertex Pharmaceuticals Incorporated Animal model for protease activity and liver damage
US7897146B2 (en) * 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7319015B2 (en) * 2004-03-16 2008-01-15 The Regents Of The University Of Michigan Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en) * 2004-03-16 2009-09-01 The Regents Of The University Of Michigan Methods and compositions for using aleveolar macrophage phospholipase A2
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006014798A2 (en) * 2004-07-27 2006-02-09 Mount Sinai School Of Medicine Methods and compositions for using sax2
FI20050753L (fi) 2004-09-03 2006-03-04 Licentia Oy Uudet peptidit
EP1853628B1 (de) * 2005-02-17 2015-08-19 Vertex Pharmaceuticals Incorporated Spleissvariante der alpha-untereinheit des typ iii natriumkanals
WO2007016239A2 (en) * 2005-07-29 2007-02-08 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
DE602006020881D1 (de) 2005-08-15 2011-05-05 Vegenics Pty Ltd Enen eigenschaften
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
DK1969003T3 (da) 2005-12-14 2010-12-13 Hermo Pharma Ltd Anvendelser af et neurotrofisk faktor-protein
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
ES2497641T3 (es) 2006-05-17 2014-09-23 The Ludwig Institute For Cancer Research Dirección a la regulación de VEGF-B de transportadores de ácidos grasos para modular enfermedades humanas
US8586028B2 (en) * 2007-05-09 2013-11-19 Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EP2318036B1 (de) 2008-06-30 2015-06-03 The Regents of the University of Michigan Aktivität von lysosomaler phospholipase a2 (lpla2) als diagnostisches und therapeutisches target zur identifizierung und behandlung von systemischem lupus erythematodes
ES2748577T3 (es) 2011-05-19 2020-03-17 Univ Michigan Regents Agentes de fijación de la integrina alfa-2 y uso de los mismos para inhibir la proliferación de las células de cáncer
LT2751279T (lt) 2011-08-31 2017-12-11 St. Jude Children`S Research Hospital Būdai ir kompozicijos lizosominės egzocitozės aktyvumo lygio nustatymui ir panaudojimo būdai
WO2013079687A1 (en) 2011-11-30 2013-06-06 The Chancellor, Masters And Scholars Of The University Of Oxford Inkt cell modulators and methods of using the same
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
CN104520315A (zh) 2012-04-24 2015-04-15 迈阿密大学 Perforin 2 对侵袭性且多药耐受的病原体的防御
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
RS61985B1 (sr) 2012-09-06 2021-07-30 Univ Chicago Antisens polinukleotidi za indukovanje preskakanja egzona i postupci lečenja distrofija
JP6408492B2 (ja) 2013-02-18 2018-10-17 ヴェジェニクス プロプライエタリー リミテッドＶｅｇｅｎｉｃｓ Ｐｔｙ Ｌｉｍｉｔｅｄ リガンド結合分子およびその使用
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
US20160250303A1 (en) 2013-10-09 2016-09-01 University Of Miami Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation
PT3283500T (pt) 2015-04-08 2021-01-28 Univ Chicago Composições e métodos para corrigir distrofia muscular das cinturas tipo 2c com utilização de salto do exão
WO2017118866A1 (en) 2016-01-08 2017-07-13 Replimune Limited Engineered virus
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CA3103169A1 (en) 2018-06-11 2019-12-19 University Of Florida Research Foundation, Inc. Materials and methods for treating stress-related disorders and cancer
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US4999296A (en) * 1986-04-29 1991-03-12 Novagene, Inc. Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form

Also Published As

Publication number Publication date
AU658838B2 (en) 1995-05-04
EP0500917A1 (de) 1992-09-02
ATE152355T1 (de) 1997-05-15
DK0500917T3 (da) 1997-10-27
US6120773A (en) 2000-09-19
US5328688A (en) 1994-07-12
WO1992004050A1 (en) 1992-03-19
CA2072627A1 (en) 1992-03-11
ES2102409T3 (es) 1997-08-01
CA2072627C (en) 2003-12-16
DE69125925T2 (de) 1997-09-25
JP3334876B2 (ja) 2002-10-15
EP0500917A4 (en) 1993-02-17
EP0500917B1 (de) 1997-05-02
JPH05503017A (ja) 1993-05-27
GR3024144T3 (en) 1997-10-31
AU8741891A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
DE69125925D1 (de) Rekombinante herpes simplex virus impfstoffe und methoden
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ES8202584A1 (es) Un procedimiento para la preparacion de una vacuna viral vi-va estabilizada y mejorada.
DK0595873T3 (da) Negativt cytosindeaminaseselektionssystem til gentransferteknikker og -terapier
DE69114997D1 (de) Von Adeno-assoziierte Viren rekombinante Vektoren.
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
HK1019233A1 (en) Animal cells and processes for the replication of influenza viruses
AU6489986A (en) Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
IL77694A (en) Canine parvovirus vaccines comprising viruses of the canine parvovirus strain 154 or viruses derived therefrom by additional cell culture passaging
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
ES8505253A1 (es) Un procedimiento para preparar un organismo unicelular que tiene una secuencia de adn que codifica un plipeptid0 que tiene un determinante inmunorreactivo u antigeno de una glicoproteina de virus de herpes simplex.
ES468363A1 (es) Proceso para la fabricacion de un preparado destinado al tra-tamiento de herpes-zoster.
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
HUP0001991A2 (hu) Varicella Zoster vírus 63-as géntermékkel szembeni vakcinák
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
ATE223492T1 (de) Mutanten des infektiösen rinder rhinotracheitis- virus und impfstoffe
EP0326127A3 (de) Infektiöse Rinder-Rhinotracheitis-Virus-Insertionsmutanten, sie enthaltende Impfstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
DK498387D0 (da) Virus-dna-sekvens
MX9602256A (es) Vacuna contra la enfermedad de marek.
AU7514087A (en) Vaccine containing the protein f of the aids virus
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained

Legal Events

Date Code Title Description
8363 Opposition against the patent